Get started
Author

Nicolas Demogeot

Observed names: Demogeot, Nicolas, N. Demogeot, Nicolas DEMOGEOT
ORCID: 0000-0003-4730-1161
Observed ORCID: 0000-0003-4730-1161
OpenAlex ID: A5000497283
Artificial intelligence contouring in radiotherapy for organs-at-risk and lymph node areas
2024 · Céline Meyer, Sandrine Huger, et al. · Radiation Oncology · 17
PDF
Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial
2025 · Nicolas Demogeot, Paul Sargos, et al. · European Urology · 7
Outcomes following brachytherapy boost for intermediate- and high-risk prostate cancer: A retrospective bicenter study by the SFRO brachytherapy group
2023 · Kanta Ka, Renaud Schiappa, et al. · Radiotherapy and Oncology · 7
PDF
Pattern of recurrence after fractionated stereotactic reirradiation in adult glioblastoma
2025 · Agathe Margulies, Nassim Sahki, et al. · Radiation Oncology · 6
Hypofractionated radiotherapy for invasive squamous cell carcinoma of the scalp in the elderly: Efficacy and tolerance, preliminary results
2023 · J. Jacques, S. Renard, et al. · Cancer/Radiothérapie · 6
PDF
Oncological Outcomes and Organ Preservation After Brachytherapy for Penile Carcinoma: A Multicentric Retrospective Study by the Brachytherapy Group of the French Society for Radiation Oncology
2025 · Kanta Ka, Abel Cordoba, et al. · International Journal of Radiation Oncology*Biology*Physics · 4
Local control and recurrence patterns after stereotactic irradiation delivered in more than 4 fractions for hepatocellular carcinomas and liver metastases: a retrospective study
2025 · Alizée Renan, Marie Bruand, et al. · Radiation Oncology · 4
PDF
Brachytherapy for favorable prognostic prostate cancer in men up to 60 years of age: Long term follow-up
2024 · Juliette Jacques, Nassim Sahki, et al. · Brachytherapy · 4
PDF
Adjuvant pulse-dose-rate brachytherapy for oral cavity and oropharynx carcinoma: Outcome and toxicity assessment of 66 patients
2024 · Sophie Renard, Nicolas Demogeot, et al. · Journal of Contemporary Brachytherapy · 4
PDF
Impact of fractionated stereotactic radiotherapy on activity of daily living and performance status in progressive/recurrent glioblastoma: a retrospective study
2022 · Nicolas Demogeot, J. Salleron, et al. · Radiation Oncology · 4
PDF
Radiotherapy with twice weekly Gemcitabine and Cisplatin compared to Cisplatin alone for organ preservation in muscle-invasive bladder cancer: results of the GETUG V04 randomized phase II trial
2026 · Morgan Michalet, Philippe Ronchin, et al. · Radiotherapy and Oncology · 2
Short-Term Androgen Deprivation Therapy and High-Dose Radiotherapy in Intermediate- and High-Risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase III Trial
2024 · N. Demogeot, P. Sargos, et al. · International Journal of Radiation Oncology*Biology*Physics · 2
PDF
SPINAL: study protocol for a multicenter non-inferiority trial evaluating reduce vertebral irradiation volumes in palliative radiotherapy for spinal bone metastases on analgesic efficacy
2026 · Jean-Christophe Faivre, Aurélien Lambert, et al. · BMC Cancer · 1
Correction: Artificial intelligence contouring in radiotherapy for organs-at-risk and lymph node areas
2025 · Céline Meyer, Sandrine Huger, et al. · Radiation Oncology · 1
Randomized phase III trial with a factorial design assessing the efficacy and safety of darolutamide and stereotactic dose-escalated radiotherapy in patients with high-risk localized prostate cancer: the PEACE 7 (GETUG-AFU 45) study protocol
2026 · Gilles Crehange, Pierre Blanchard, et al. · BMC Cancer
4897 Surface Brachytherapy versus VMAT for Scalp Skin Tumors: A Dosimetric Comparison
2026 · Céline Meyer, Nicolas Demogeot, et al. · Radiotherapy and Oncology
1609 PROTECT-DTI: A Multicenter Federated Imaging and Clinical Integration Program to Preserve White Matter in Stereotactic Brain Radiotherapy
2026 · Paul RETIF, Markus HECHT, et al. · Radiotherapy and Oncology
In Reply to May et al.
2026 · Kanta Ka, Abel Cordoba, et al. · PubMed
Reply to Federico Iori, Emanuele Alì, and Cinzia Iotti’s Letter to the Editor re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. Eur Urol. 88;2025:88:510–518.
2025 · Nicolas Demogeot, Stéphane Supiot, et al. · European Urology
Reply to Mattia Longoni, Giorgio Gandaglia, and Francesco Montorsi’s Letter to the Editor re: Nicolas Demogeot, Paul Sargos, Julia Salleron, et al. Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. Eur Urol. 88;2025:510–518
2025 · Nicolas Demogeot, Stéphane Supiot, et al. · European Urology
Transition from pulsed dose rate to high dose rate brachytherapy: Experience of a single centre
2025 · S. Renard, E. Meknaci, et al. · Brachytherapy
PDF
3104 Artificial Intelligence contouring in radiotherapy for organs-at-risk and lymph node areas
2025 · Céline Meyer, Sandrine Huger, et al. · Radiotherapy and Oncology
725 Concurrent chemoradiotherapy with Cisplatin and Gemcitabine in muscle-invasive bladder cancer: results of a prospective phase II trial (NCT01495676)
2025 · Morgan Michalet, Philippe Ronchin, et al. · Radiotherapy and Oncology
540 Liver SBRT in more than 4 fractions: local control and recurrence patterns
2025 · Alizée Renan, Nicolas Demogeot, et al. · Radiotherapy and Oncology
1457 Outcomes of whole-brain radiotherapy with stereotactic boost using HyperArc mono-isocentric radiosurgery: a single-institution study of 105 patients.
2025 · Camille Streiff, Nicolas Demogeot, et al. · Radiotherapy and Oncology
Works count: 32
Citation count: 69
H-index: 5
I10-index: 1
Year
Topic
Type